Navigation Links
Statins have neutral effect on risk of cancer

The cholesterol-lowering medications called statins do not appear to reduce the incidence of cancer or cancer deaths, according to a meta-analysis of previous studies in the January 4 issue of JAMA.

Other studies have suggested that statins reduce the risk of developing cancer, the authors provide as background information in the review article. "Statins have been studied in numerous large-scale, randomized, active- or placebo-controlled trials for primary and secondary prevention of coronary artery disease. In these trials, statins reduced the risk of a first myocardial infarction (heart attack) and overall mortality. With long-term follow-up and collection of cancer data in a majority of studies, insight into the risk of cancer among statin-naïve persons and statin users can be derived," the authors write.

C. Michael White, Pharm.D., from the University of Connecticut and Hartford Hospital, Hartford, Conn., and colleagues, conducted a search of the medical literature from 1966 through July 2005 to identify randomized controlled trials of statins. They found 27 articles (n = 86,936 participants) that met their criteria for inclusion, reporting 26 randomized controlled trials of statins with data on either cancer incidence (n = 20 studies) or cancer death (n = 22 studies).

"In our current meta-analysis, statins did not reduce the incidence of cancer or cancer death," the authors report. "No reductions were noted for cancers of the breast, colon, gastrointestinal tract, prostate, respiratory tract, or skin (melanoma) when statins were used." The authors continue, "?the patients in our meta-analysis were primarily treated with simvastatin and pravastatin. As such, we evaluated pravastatin alone and simvastatin alone on cancer incidence and death and found no impact."

"Statins have a neutral effect on cancer and cancer death risks in randomized controlled trials," the authors write in conclusion. "We could find no type of c ancer that statins benefited or subtype of statin that reduced the risk of cancer.


Source:JAMA and Archives Journals

Related biology news :

1. Statins stop hepatitis C virus from replicating
2. Defensins neutralize anthrax toxin
3. Bleach found to neutralize mold allergens
4. Human trial proves ricin vaccine safe, induces neutralizing antibodies; further tests planned
5. Scientific issues associated with carbon-neutral energy sources such as cellulosic ethanol
6. Scientists ID molecular switch in liver that triggers harmful effects of saturated and trans fats
7. Combination therapy boosts effectiveness of telomere-directed cancer cell death
8. New imaging method gives early indication if brain cancer therapy is effective, U-M study shows
9. Alcohols effects on gene expression in the central nervous system
10. Boosting HIV screening can increase survival and is cost effective
11. Liposome finding implies electrical effect on cell development
Post Your Comments:

(Date:9/29/2015)... , Sept. 29, 2015 ... employee productivity while also saving energy , Minimized ... as Low Power Active Mode and embedded Fujitsu PalmSecure ... Fujitsu today shows that good things ... and refreshed models to its enterprise desktop and mobile ...
(Date:9/28/2015)... YORK , Sept. 28, 2015 /PRNewswire/ ... announced today that its expedited traveler service ... innovative platform transforms travel, bringing a frictionless ... its members. "CLEAR offers our ... enhances customer service," said Jim Smith ...
(Date:9/28/2015)... SAN FRANCISCO , September 28, 2015 ... size is expected to reach USD 12.03 billion by ... to 2020. Technological advancements such as Backside Illumination (BSI) ... revenue growth over the forecast period.      ... the back of the chip to reduce loss and, ...
Breaking Biology News(10 mins):
(Date:10/13/2015)... JACKSONVILLE, Florida , October 13, 2015 ... company specializing in the development of innovative peptide and ... & metastatic disease, will be a featured presenting company ... at the Wyndham Grand Hotel in ... --> TapImmune, Inc. (TPIV), a clinical-stage immunotherapy ...
(Date:10/13/2015)... Mass. and TORONTO , Oct. ... GNBT) today announced that it has entered into a non-binding ... ), a private Israeli company that has developed a proprietary ... infertile due to varicoceles. the United States ... between the ages of 25 and 44 diagnosed ...
(Date:10/13/2015)... (PRWEB) , ... October 13, 2015 , ... Clinovo recently ... expertise to the company’s fast growing clinical data solutions business. , Jeff Parr has ... companies of all sizes, including Avery Dennison, Thermo Fisher, and Ab Sciex to name ...
(Date:10/13/2015)... (PRWEB) , ... October 13, 2015 , ... ... personalized medicine, is excited to announce their partnership with the Keck Medicine ... genetics of chronic pain. , The T.R.O.J.A.N. Study (Therapeutic Evaluation to Research Clinical ...
Breaking Biology Technology: